264 related articles for article (PubMed ID: 10372604)
21. Partial compliance in schizophrenia and the impact on patient outcomes.
Llorca PM
Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
[TBL] [Abstract][Full Text] [Related]
22. Quetiapine: efficacy, tolerability and safety in schizophrenia.
Miodownik C; Lerner V
Expert Rev Neurother; 2006 Jul; 6(7):983-92. PubMed ID: 16831113
[TBL] [Abstract][Full Text] [Related]
23. Partial response to antipsychotic treatment: the patient with enduring symptoms.
Emsley RA
J Clin Psychiatry; 1999; 60 Suppl 23():10-3. PubMed ID: 10625194
[TBL] [Abstract][Full Text] [Related]
24. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
25. Iloperidone for the treatment of schizophrenia: an updated clinical review.
Weiden PJ
Clin Schizophr Relat Psychoses; 2012 Apr; 6(1):34-44. PubMed ID: 22453868
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
27. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
Bhanji NH; Chouinard G; Margolese HC
Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
[TBL] [Abstract][Full Text] [Related]
28. Strategies for dosing and switching antipsychotics for optimal clinical management.
Buckley PF; Correll CU
J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
[TBL] [Abstract][Full Text] [Related]
30. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
Kilian R; Angermeyer MC
Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
[TBL] [Abstract][Full Text] [Related]
31. Schizophrenia.
Marder SR; Ames D; Wirshing WC; Van Putten T
Psychiatr Clin North Am; 1993 Sep; 16(3):567-87. PubMed ID: 8105452
[TBL] [Abstract][Full Text] [Related]
32. The case for long-acting antipsychotic agents in the post-CATIE era.
Nasrallah HA
Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
[TBL] [Abstract][Full Text] [Related]
33. Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence.
Chan J; Sweeting M
J Psychopharmacol; 2007 Aug; 21(6):657-64. PubMed ID: 17092976
[TBL] [Abstract][Full Text] [Related]
34. Dose response of prophylactic antipsychotics.
Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
[TBL] [Abstract][Full Text] [Related]
35. Annual health outcomes and treatment costs for schizophrenia populations.
Mauskopf JA; David K; Grainger DL; Gibson PJ
J Clin Psychiatry; 1999; 60 Suppl 19():14-9; discussion 20-2. PubMed ID: 10507276
[TBL] [Abstract][Full Text] [Related]
36. Evaluating clinical trial data: outcome measures.
Conley RR
J Clin Psychiatry; 2001; 62 Suppl 9():23-6; discussion 27-8. PubMed ID: 11379827
[TBL] [Abstract][Full Text] [Related]
37. Choice of maintenance medication for schizophrenia.
Davis JM; Chen N
J Clin Psychiatry; 2003; 64 Suppl 16():24-33. PubMed ID: 14680416
[TBL] [Abstract][Full Text] [Related]
38. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment.
Altamura AC; Bobo WV; Meltzer HY
Int Clin Psychopharmacol; 2007 Sep; 22(5):249-67. PubMed ID: 17690594
[TBL] [Abstract][Full Text] [Related]
39. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
Agid O; Foussias G; Remington G
Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
[TBL] [Abstract][Full Text] [Related]
40. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
Naber D; Lambert M; Karow A
Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
